Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAMPEDE trial in advanced or metastatic prostate cancer
ISRCTN78818544Phase 3Completed
- Sponsor
- University College London
- Start
- Oct 2005
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of metformin, oestradiol, docetaxel, abiraterone, enzalutamide and 2 more in prostate adenocarcinoma (11 arms), sponsored by University College London. Primary endpoints: Safety, Failure-free survival and 1 more. Started Oct 2005; status: completed.
02
Drugs
metforminoestradioldocetaxelabirateroneenzalutamide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on ISRCTN78818544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN78818544.